Home/Pipeline/GM-CSF

GM-CSF

Not Specified (Animal)

Phase IIIActive

Key Facts

Indication

Not Specified (Animal)

Phase

Phase III

Status

Active

Company

SYTE.bio

About SYTE.bio

SYTE.bio is a private, clinical-stage biotech leveraging synthetic biology to create non-viral DNA and RNA therapeutics and vaccines for human and animal health. The company has advanced its lead animal oncology program, INVIVO-mAb Anti CTLA4, into Phase III trials, demonstrating progress in its pipeline. With a dual-platform technology strategy and a focus on safety and efficacy, SYTE.bio aims to address unmet needs in areas like oncology, chronic diseases, and infectious diseases. The company operates with a global footprint, including offices in Boston and Buenos Aires.

View full company profile

Therapeutic Areas

Oncology Infectious Disease Chronic Disease Pain Dermatology Veterinary Health

Other Not Specified (Animal) Drugs

Drug	Company	Phase	Status
IL-12	SYTE.bio	Phase III	Active
INVIVO-mAb Anti PDL-1	SYTE.bio	Pre-Clinical	Active
INVIVO-mAb Bi-Specific	SYTE.bio	Research	Active